Pharma commercial intelligence, news & analysis

Evaluate radically transforms your confidence in strategic portfolio decisions.

When you partner with Evaluate, our constantly expanding solutions and transparent methodologies and datasets are instantly at your disposal, along with expert, personalised support.

Evaluate provides a complete and dynamic valuation of pharma assets, turning understanding into insight, and insight into action.

HOW WE CAN HELP YOU

Market Reports

Thought Leadership

Read our wide range of complimentary market reports covering sector performance and valuation, market trends and global forecasts, including our annual Evaluate Pharma World Preview.

READ OUR REPORTS

OUR PRODUCTS

Evaluate Pharma

Get a global view of the pharmaceutical market’s past, present and future performance with over two decades of commercial data and consensus forecasts to 2026.

FIND OUT MORE

OUR SERVICES

Pharma Consulting & Analytics

Improve your strategic decision-making with customised, data-driven solutions that draw on our collaborative team of industry experts and trusted commercial intelligence.

FIND OUT MORE

September 30, 2022

Fourth-quarter data for the little guys

Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.

September 29, 2022

Go or no go? GSK takes its turn with a novel anaemia class

Amicus and Astrazeneca have notable approaching Pdufa decisions, while a panel for GSK’s daprodustat could change the course of a controversial drug class.

September 29, 2022

Ember burns bright for Angle

September 28, 2022

Lecanemab can; now the wait for details begins